Membrane Perturbations and Assay Interferences by Ivermectin Explain Its In Vitro SARS-CoV‑2 Antiviral Activities and Lack of Translatability

Membrane Perturbations and Assay Interferences by Ivermectin Explain Its In Vitro SARS-CoV‑2 Antiviral Activities and Lack of Translatability

The antiparasitic drug ivermectin was proposed as a repurposed drug for the treatment of SARS-CoV-2 infection based on in vitro studies, but proved ineffective in high-quality clinical trials. When exploring possible reasons for this disconnect, we found that ivermectin interferes with AlphaScreen a...

保存先:

書誌詳細
第一著者:	Richard T. Eastman (6051881) (author)
その他の著者:	Radda Rusinova (4870042) (author), Karl F. Herold (605487) (author), Xi-Ping Huang (391870) (author), Ty Voss (12046550) (author), Alex D. White (7356104) (author), Hugh C. Hemmings (1330833) (author), Olaf S. Andersen (823886) (author), Jayme L. Dahlin (486120) (author)
出版事項:	2025
主題:	Biochemistry Medicine Pharmacology Biotechnology Cancer Infectious Diseases Virology Computational Biology Chemical Sciences not elsewhere classified Information Systems not elsewhere classified quality clinical trials perturbing bioactivity early low nanomolar concentrations low micromolar concentrations highlight lessons learned exploring possible reasons 2 viral burden 2 infection based safe antiparasitic drug antiparasitic drug ivermectin ivermectin reduced sars effective antiviral agent antiviral agent repurposed drug drug development pursuing ivermectin ivermectin interferes ivermectin explain proved ineffective perspective </ original justifications membrane perturbations level rationale identifying membrane becomes cytotoxic assay interferences alphascreen assays
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料

Membrane Perturbations and Assay Interferences by Ivermectin Explain Its In Vitro SARS-CoV‑2 Antiviral Activities and Lack of Translatability
著者:: Richard T. Eastman (6051881)
出版事項: (2025)

Membrane Perturbations and Assay Interferences by Ivermectin Explain Its In Vitro SARS-CoV‑2 Antiviral Activities and Lack of Translatability
著者:: Richard T. Eastman (6051881)
出版事項: (2025)

Table 1_Efficacy and safety of oral ivermectin versus benzyl benzoate for the treatment of scabies: a systematic review and meta-analysis of randomized controlled trials.docx
著者:: Ahmed Abu-Zaid (8896541)
出版事項: (2025)

Table 1_Assessing the diagnostic value of qPCR for Trichuris trichiura: sub-analysis of a multi-country clinical trial to determine the efficacy of albendazole compared to an albendazole-ivermectin fixed dose combination.docx
著者:: Pedro E. Fleitas (8704023)
出版事項: (2025)

Larval development on ivermectin aglycone plates.
著者:: Jennifer McIntyre (6237104)
出版事項: (2025)

ED50s and resistance ratios (RR) from larval development assays on ivermectin plates.
著者:: Jennifer McIntyre (6237104)
出版事項: (2025)

RNA-seq data for male and female adults after third generation of ivermectin or moxidectin selection.
著者:: Jennifer McIntyre (6237104)
出版事項: (2025)

Supplementary file 1_Dose-dependent modulation of hepatic cytochrome P450 enzymes by tenvermectin: implications for medication safety and combination therapy.docx
著者:: Jianping Liang (501330)
出版事項: (2025)

Cochran-Mantel-Haenszel test showing common selection within and across ivermectin and moxidectin treatment sample groups.
著者:: Jennifer McIntyre (6237104)
出版事項: (2025)

Ivermectin dose (µg/kg) distribution across dosing regimens.
著者:: Adriana Echazu (12047496)
出版事項: (2025)

Treatment efficacy and faecal egg count reduction (FECR) after treatment with a half dose of ivermectin or moxidectin. Negative values indicate zero efficacy.
著者:: Jennifer McIntyre (6237104)
出版事項: (2025)

Treatment efficacy and faecal egg count reduction (FECR) after treatment of ivermectin-selected and control lines with moxidectin. Negative values indicate zero efficacy.
著者:: Jennifer McIntyre (6237104)
出版事項: (2025)

Half inhibitory concentration (IC<sub>50</sub>) of IVM in a breast cancer cell line at different exposure times.
著者:: Kitiya Rujimongkon (7163912)
出版事項: (2025)

Effect of IVM on the expression and localization of β-catenin in endocrine-resistance cell lines.
著者:: Kitiya Rujimongkon (7163912)
出版事項: (2025)

The influence of IVM on Wnt signaling proteins in endocrine-resistant breast cancer cell lines: MCF-7/LCC2 and MCF-7/LCC9.
著者:: Kitiya Rujimongkon (7163912)
出版事項: (2025)

IVM impact on EMT markers in breast cancer cell lines: MCF-7/LCC2 and MCF-7/LCC9.
著者:: Kitiya Rujimongkon (7163912)
出版事項: (2025)

IVM inhibited the invasion of endocrine-resistant breast cancer cells.
著者:: Kitiya Rujimongkon (7163912)
出版事項: (2025)

IVM inhibited cell migration in endocrine-resistant breast cancer cells.
著者:: Kitiya Rujimongkon (7163912)
出版事項: (2025)

IVM inhibited the growth of endocrine-resistant breast cancer cell lines.
著者:: Kitiya Rujimongkon (7163912)
出版事項: (2025)

Treatment efficacy and faecal egg count reduction (FECR) from three generations of selection with ivermectin or moxidectin using pre- and post-treatment faecal egg counts from each donor.
著者:: Jennifer McIntyre (6237104)
出版事項: (2025)

Flow diagram of participants of the Individual participant data meta-analysis of ivermectin fixed-dose feasibility.
著者:: Adriana Echazu (12047496)
出版事項: (2025)

Percentiles of calculated amount of ivermectin required for reaching the recommended dose (200 µg/kg) by age (N = 741,700).
著者:: Adriana Echazu (12047496)
出版事項: (2025)

Ivermectin dose (µg/kg) by sex in school-age children (SAC) receiving a fixed 9 mg dose.
著者:: Adriana Echazu (12047496)
出版事項: (2025)

Ivermectin dose (µg/kg) by sex in pre-school-age children (PSAC) receiving a fixed 3 mg dose.
著者:: Adriana Echazu (12047496)
出版事項: (2025)

The emergence of resistance to multiple acaricides in the cattle tick <i>Rhipicephalus microplus</i> (Acari: Ixodidae) in the northwestern Himalayan region of India: a study
著者:: Devina Sharma (11179275)
出版事項: (2025)

(n = 317,401): Panel A: Correlation between height and weight of pre-school age children (PSAC); Panel B: weight for height percentiles of PSAC participants of the study; Panel C: Distribution of ivermectin dose (µg/kg) by year of age in PSAC using the fixed-dose regimen.
著者:: Adriana Echazu (12047496)
出版事項: (2025)

Differentially expressed genes shared in all four pairwise comparisons at adjusted P < 0.01.
著者:: Jennifer McIntyre (6237104)
出版事項: (2025)

Number of SNPs identified as significant by the Cochran-Mantel-Haenzel test.
著者:: Jennifer McIntyre (6237104)
出版事項: (2025)

Change from F0 to F3 in the reference allele frequency of individual SNPs located between Chromosome V:30-45 Mb.
著者:: Jennifer McIntyre (6237104)
出版事項: (2025)

Tajima’s D along Chromosome V in all samples calculated in 100 kb windows using a subsampled depth of 57X.
著者:: Jennifer McIntyre (6237104)
出版事項: (2025)

Nucleotide diversity (θπ) along Chromosome V in all samples calculated in 100 kb windows using a subsampled depth of 57X.
著者:: Jennifer McIntyre (6237104)
出版事項: (2025)

Pool-seq F<sub>st</sub> plots from three generations of sub-therapeutic selection.
著者:: Jennifer McIntyre (6237104)
出版事項: (2025)

Differentially expressed genes in IVM and MOX selected male and female adults versus controls.
著者:: Jennifer McIntyre (6237104)
出版事項: (2025)

Negative and significant SNPs from allele frequency model.
著者:: Jennifer McIntyre (6237104)
出版事項: (2025)

Larval development assays on thiabendazole and tetramisole plates.
著者:: Jennifer McIntyre (6237104)
出版事項: (2025)

Sample data for ENA.
著者:: Jennifer McIntyre (6237104)
出版事項: (2025)

Sample details for ENA.
著者:: Jennifer McIntyre (6237104)
出版事項: (2025)

Proportion of participants within each dosing category by dosing regimen (N = 741.700).
著者:: Adriana Echazu (12047496)
出版事項: (2025)

pntd.0013059.t003 -
著者:: Adriana Echazu (12047496)
出版事項: (2025)

Proportion of participants per dose category and by dosing method for each age group.
著者:: Adriana Echazu (12047496)
出版事項: (2025)